

## WuXi ATU announces launch of TESSA Technology

08 March 2022 | News

TESSA technology provides a scalable process for manufacturing gene therapies



WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA<sup>™</sup>). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA<sup>™</sup> will expedite AAV manufacturing and significantly reduce the cost for manufacturing cell and gene therapies, enabling global customers to deliver more accessible ground-breaking therapeutics to patients as quickly as possible.

AAV vector is a popular tool for the delivery of gene therapies in diseases such as haemophilia and Alzheimer's. Efficient processes for manufacturing AAV on a large scale are critical to meeting increasing industry demands. TESSA<sup>™</sup> vectors can meet the scalability challenges of AAV production, which has significant implications for expanding patient access to these novel therapeutics.

The new data published in <u>Nature Communications</u> supports the benefits of this technology. It highlights that in the same manufacturing volume, TESSA<sup>™</sup> vectors produced 10 times more AAV than plasmid-based manufacture, producing enough material to treat ten times the number of patients.